Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2015

1 of 4
Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2015

Summary

The report ‘Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2015’, provides an overview of the Takeda Pharmaceutical Company Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Takeda Pharmaceutical Company Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Takeda Pharmaceutical Company Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Takeda Pharmaceutical Company Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Takeda Pharmaceutical Company Limited’s pipeline products

Reasons to buy

- Evaluate Takeda Pharmaceutical Company Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Takeda Pharmaceutical Company Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Takeda Pharmaceutical Company Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Takeda Pharmaceutical Company Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Takeda Pharmaceutical Company Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Takeda Pharmaceutical Company Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Takeda Pharmaceutical Company Limited Snapshot

Takeda Pharmaceutical Company Limited Overview

Key Information

Key Facts

Takeda Pharmaceutical Company Limited - Research and Development Overview

Key Therapeutic Areas

Takeda Pharmaceutical Company Limited - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Takeda Pharmaceutical Company Limited - Pipeline Products Glance

Takeda Pharmaceutical Company Limited - Late Stage Pipeline Products

Takeda Pharmaceutical Company Limited - Clinical Stage Pipeline Products

Takeda Pharmaceutical Company Limited - Early Stage Pipeline Products

Takeda Pharmaceutical Company Limited - Drug Profiles

(alogliptin benzoate + metformin hydrochloride)

(alogliptin benzoate + pioglitazone hydrochloride)

alogliptin benzoate

ceftaroline fosamil

glatiramer acetate

haemophilus influenzae [serotype B] vaccine

ramelteon

roflumilast

vedolizumab

(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide)

azilsartan medoxomil

febuxostat XR

immune globulin (human)

rasagiline mesylate

trebananib

vortioxetine hydrobromide

risedronate sodium

AM-4

DSM-265

MLN-1202

motesanib diphosphate

namilumab

relugolix

TAK-003

TAK-063

TAK-114

TAK-214

TAK-272

TAK-850

fulranumab

TAK-020

TAK-021

TAK-058

TAK-079

TAK-233

TAK-648

TAK-915

TAK-935

tedatioxetine

BTZO-15

BTZO-2

chikungunya vaccine

ELQ-300

influenza [strain H5N1] vaccine

influenza vaccine

mapatumumab

modified vaccinia ankara vaccine

Monoclonal Antibody Conjugate for Cancer

Monoclonal Antibody Conjugated to Target c-Ret for Breast Cancer

respiratory syncytial virus vaccine

rotavirus vaccine

RUSKI-43

Small Molecule to Activate Glucokinase for Type 2 Diabetes

Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain

Small Molecule to Agonize GPR52 for Psychiatry Disorders

Small Molecule to Antagonize Androgen Receptor for Prostate Cancer

Small Molecule to Antagonize Mineralocorticoid Receptor for Hypertension

Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder

Small Molecule to Antagonize PDGFR and VEGFR-2 for Cancer

Small Molecule to Inhibit BTK for Rheumatoid Arthritis

Small Molecule to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression

Small Molecule to Inhibit FAAH for Pain

Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia

Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease

Small Molecule to Inhibit HER2/EGFR for Cancer

Small Molecule to Inhibit MCHR1 for Obesity

Small Molecule to Inhibit Serotonin-Norepinephrine-Dopamine Reuptake for Depression

Small Molecules for Cognitive Impairment Associated with Schizophrenia

Small Molecules for Parkinson's Disease

Small Molecules for Visceral Leishmaniasis

Small Molecules to Agonize GPR119 for Type II Diabetes

Small Molecules to Antagonize c-Met and VEGFR2 for Cancer

Small Molecules to Inhibit Acetyl-CoA Carboxylase for Obesity

Small Molecules to Inhibit CENP-E for Cancer

Small Molecules to Inhibit DPP-IV for Type 2 Diabetes

Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma

Small Molecules to Inhibit PARP-1 for Cancer

Stem Cell Therapy for Muscular Dystrophy

T-1840383

T-3256336

TAK-075

TAK-480

TAK-632

TAK-792

Y-443

Antibodies for Undisclosed Indication

Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis

Small Molecule for Undisclosed Indication

Small Molecule to Inhibit Arginine Methyltrasferase for Cancer

Small Molecule to Inhibit FAK for Cancer

Small Molecule to Inhibit HDAC6 for Undisclosed Indication

Small Molecule to Inhibit HER2 and EGFR for Cancer

Small Molecule to Inhibit IAP for Cancer

Small Molecules for Malaria

Small Molecules for Tuberculosis

Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 for Undisclosed Indication

Small Molecules to Inhibit Mcl-1 and Bcl-xL for Cancer

Small Molecules to Inhibit MMP-13 for Osteoarthritis

Y-142

Takeda Pharmaceutical Company Limited - Pipeline Analysis

Takeda Pharmaceutical Company Limited - Pipeline Products by Target

Takeda Pharmaceutical Company Limited - Pipeline Products by Route of Administration

Takeda Pharmaceutical Company Limited - Pipeline Products by Molecule Type

Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action

Takeda Pharmaceutical Company Limited - Recent Pipeline Updates

Takeda Pharmaceutical Company Limited - Dormant Projects

Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Takeda Pharmaceutical Company Limited - Company Statement

Takeda Pharmaceutical Company Limited - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Takeda Pharmaceutical Company Limited - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Takeda Pharmaceutical Company Limited, Key Information

Takeda Pharmaceutical Company Limited, Key Facts

Takeda Pharmaceutical Company Limited - Pipeline by Indication, 2015

Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2015

Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2015

Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2015

Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2015

Takeda Pharmaceutical Company Limited - Partnered Products/ Combination Treatment Modalities, 2015

Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2015

Takeda Pharmaceutical Company Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015

Takeda Pharmaceutical Company Limited - Pre-Registration, 2015

Takeda Pharmaceutical Company Limited - Filing rejected/Withdrawn, 2015

Takeda Pharmaceutical Company Limited - Phase III, 2015

Takeda Pharmaceutical Company Limited - Phase II, 2015

Takeda Pharmaceutical Company Limited - Phase I, 2015

Takeda Pharmaceutical Company Limited - Preclinical, 2015

Takeda Pharmaceutical Company Limited - Discovery, 2015

Takeda Pharmaceutical Company Limited - Pipeline by Target, 2015

Takeda Pharmaceutical Company Limited - Pipeline by Route of Administration, 2015

Takeda Pharmaceutical Company Limited - Pipeline by Molecule Type, 2015

Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action, 2015

Takeda Pharmaceutical Company Limited - Recent Pipeline Updates, 2015

Takeda Pharmaceutical Company Limited - Dormant Developmental Projects,2015

Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products, 2015

Takeda Pharmaceutical Company Limited, Subsidiaries

Takeda Pharmaceutical Company Limited, Key Manufacturing Facilities

List of Figures

Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Indication, 2015

Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2015

Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2015

Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2015

Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2015

Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2015

Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Target, 2015

Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Route of Administration, 2015

Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Molecule Type, 2015

Takeda Pharmaceutical Company Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll